Rimegepant is a small molecule calcitonin gene-related peptide (CGRP) receptor antagonist that is marketed under the brand name Nurtec ODT, which has been approved by the US Food and Drug Administration (FDA) for treating episodic migraines since May 2021. Nurtec medication provides fast relief and its effects can last up to 48 hours. The Biohaven migraine drug is to be taken orally to prevent migraine attacks and to reduce the number of migraine attack days in a month. In the European Union, Rimegepant is known as Vydura and is used to treat acute and episodic migraines.